Ciluprevir

Ciluprevir, also known as BILN 2061, is a potent and selective HCV NS3 protease inhibitor with proven antiviral effect in humans. In vitro sensitivity studies with BILN 2061 showed a decrease in affinity for proteases of genotypes 2 and 3 (K(i), 80 to 90 nM) compared to genotype 1 enzymes (K(i), 1.5 nM). BILN 2061 may be an antiviral agent for individuals infected with non-genotype-1 HCV.

Product information

CAS Number: 300832-84-2

Molecular Weight: 774.93

Formula: C40H50N6O8S

Synonym:

BILN 2061

BILN 2061ZW

Chemical Name: (1S,4R,6S,14S,18R)-14-{[(cyclopentyloxy)carbonyl]amino}-18-[(7-methoxy-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.0⁴,⁶]nonadec-7-ene-4-carboxylic acid

Smiles: CC(C)NC1=NC(=CS1)C1=CC(O[C@@H]2C[C@H]3C(=O)N[C@@]4(C[C@H]4C=CCCCCC[C@H](NC(=O)OC4CCCC4)C(=O)N3C2)C(O)=O)=C2C=CC(=CC2=N1)OC |c:24|

InChiKey: PJZPDFUUXKKDNB-KNINVFKUSA-N

InChi: InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Busacca CA, Jones PJ, Campbell SJ, Saha AK, Gonnella NC, Senanayake CH. Probing the cation binding modes of macrocyclic HCV protease inhibitor BILN 2061 by multinuclear NMR. J Pharm Biomed Anal. 2012 Nov;70:609-13.
2. Stoltz JH, Stern JO, Huang Q, Seidler RW, Pack FD, Knight BL. A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061. Toxicol Pathol. 2011 Apr;39(3):496-501.
3. Shu C, Zeng X, Hao MH, Wei X, Yee NK, Busacca CA, Han Z, Farina V, Senanayake CH. RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061. Org Lett. 2008 Mar 20;10(6):1303-6.

Products are for research use only. Not for human use.